Characterisation of the HLA-DRB1 * 07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and / or taxanes
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes
The Pharmacogenomics Journal advance online publication, August 8 2017.
doi:10.1038/tpj.2017.39
Authors: C F Spraggs, L R Parham, L P Briley, L Warren, L S Williams, D J Fraser, Z Jiang, Z Aziz, S Ahmed, G Demetriou, A Mehta, N Jackson, J Byrne, M Andersson, M Toi, L Harris, J Gralow, J A Zujewski, R Crescenzo, A Armour, E Perez & M Piccart
Source: The Pharmacogenomics Journal - Category: Drugs & Pharmacology Authors: C F Spraggs L R Parham L P Briley L Warren L S Williams D J Fraser Z Jiang Z Aziz S Ahmed G Demetriou A Mehta N Jackson J Byrne M Andersson M Toi L Harris J Gralow J A Zujewski R Crescenzo A Armour E Perez M Piccart Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Herceptin | Liver | Toxicology | Urology & Nephrology